arrow
S

Sofie Wilgenhof

Netherlands Cancer Institute
H指数:31
被引数:5,065

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials

同步转移性肾细胞癌中双免疫检查点抑制剂的长期真实世界生存结局:对前瞻性细胞减灭性肾切除术试验设计的启示

2025-12-190
OAAI
Health-Related Quality of Life in Adolescents and Young Adults With an Uncertain or Poor Cancer Prognosis: Quantitative Baseline Results of the CORD-AYA Study

癌症预后不确定或不良的青少年和年轻成年人的健康相关生活质量:CORD-AYA研究的定量基线结果

2025-11-210
OAAI
Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial

出版商更正: 转移性黑色素瘤的个性化自体新抗原特异性T细胞治疗: 1期试验

2025-08-040
OA
Exploring the Impact of the Multimodal CAPABLE eHealth Intervention on Health-Related Quality of Life in Patients With Melanoma Undergoing Immune-Checkpoint Inhibition: Prospective Pilot Study
2025-01-300
OA
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
2023-09-016
OAAI
Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

黑色素瘤治疗中与免疫检查点抑制剂和靶向治疗相关的常见毒性: 系统范围综述

2023-03-019
OAAI
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
2022-12-08198
OA
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR A Prospective, Single-arm, Open-label Phase II Trial
2021-04-0929
OA